Novo Nordisk: Past Peak Uncertainty?

Here’s​ a summary ⁤of the key points from⁢ the article about Novo Nordisk:

* Earnings Release: Novo⁢ Nordisk ⁢is preparing to release its third-quarter earnings on Wednesday.
* New Leadership & challenges: The company has a new​ CEO, Mark Doustdar, who took over‌ in august. He faces challenges including declining sales, profit pressure, job cuts (around ⁤9,000), adn increased ‍competition in the obesity drug market.
* Analyst Views are mixed:

*​ Berenberg: Positive, believing Novo ⁤has reached “peak uncertainty” ⁢and deserves a valuation premium due to⁣ its growth and R&D.
⁢ * Jefferies: Downgraded the stock to “underperform” due to competitive pressure and⁢ pricing concerns.
*⁤ UBS: Concerned about the ‍impact of an 8 billion Danish krone restructuring cost‍ and the company’s lack ⁤of consumer experience in the ‌US ​market.
* Trump’s Comments: U.S.President Donald Trump⁣ stated ozempic’s price ‌would be ⁢”much lower” due to administration negotiations.
* Stock Performance: The share price has been under pressure this year.